02257 SIRNAOMICS-B
- 7.000
- +0.120+1.74%
SIRNAOMICS-B News
SIRNAOMICS-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
SIRNAOMICS-B: ANNUAL REPORT 2023
SIRNAOMICS-B: VOLUNTARY ANNOUNCEMENT - SIRNAOMICS RECEIVED FDA SPECIFIC GUIDANCE FOR FURTHER DEVELOPMENT OF STP705 FOR TREATMENT OF SQUAMOUS CELL CARCINOMA IN SITU
SIRNAOMICS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
SIRNAOMICS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
SIRNAOMICS-B: INSIDE INFORMATION
SIRNAOMICS-B: NOTICE OF BOARD MEETING
SIRNAOMICS-B: ANNOUNCEMENT IN RELATION TO DEALINGS IN SECURITIES OF A DIRECTOR DURING THE BLACK-OUT PERIOD
SIRNAOMICS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
SIRNAOMICS-B: VOLUNTARY ANNOUNCEMENT - UNUSUAL SHARE PRICE MOVEMENT
SIRNAOMICS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
SIRNAOMICS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
SIRNAOMICS-B: VOLUNTARY ANNOUNCEMENT - RNAIMMUNE RECEIVES INVESTIGATIONAL NEW DRUG APPLICATION CLEARANCE FROM U.S. FDA FOR mRNA-BASED RESPIRATORY SYNCYTIAL VIRUS VACCINE RV-1770
SIRNAOMICS-B: CONNECTED TRANSACTION - GRANT OF STOCK OPTIONS BY A SUBSIDIARY TO A CONNECTED PERSON
SIRNAOMICS-B: VOLUNTARY ANNOUNCEMENT - SIRNAOMICS ANNOUNCES SUCCESSFUL COMPLETION OF COHORT 1 FROM PHASE I CLINICAL STUDY OF GALNAC-BASED RNAi THERAPEUTIC STP122G FOR ANTICOAGULANT TREATMENT
SIRNAOMICS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
SIRNAOMICS-B: GRANT OF SHARE OPTIONS
SIRNAOMICS-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
SIRNAOMICS-B: RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGES TO SENIOR MANAGEMENT
SIRNAOMICS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Analysis
Price Target
No Data
